Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Model using a peptide with carrier function for vaccination against different pathogens.

H M Etlinger1, R Knorr

  • 1Central Research Units, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Vaccine
|July 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Neuroleptic malignant syndrome].

Der Nervenarzt·2017
Same author

[Delusions: current psychodynamic and neurocognitive approaches].

Der Nervenarzt·2017
Same author

Pivaloylmetals (tBu-COM: M = Li, MgX, K) as equilibrium components.

Chemistry (Weinheim an der Bergstrasse, Germany)·2012
Same author

E/Z-equilibria. 11. Structure of a metalated Schiff base.

Journal of the American Chemical Society·2011
Same author

Transcranial perfusion sonography using a low mechanical index and pulse inversion harmonic imaging: reliability, inter-/intraobserver variability.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2010
Same author

Effects of probiotic bacteria in dogs with food responsive diarrhoea treated with an elimination diet.

Journal of animal physiology and animal nutrition·2006
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
See all related articles

Pre-immunizing mice with a protein can suppress antibody responses. However, using a carrier peptide enhances antibody production against new B-cell sequences, suggesting reusable carriers for future vaccines.

Area of Science:

  • Immunology
  • Vaccinology
  • Molecular Biology

Background:

  • Pre-immunization with proteins can lead to epitope-specific suppression of antibody responses to new B-cell sequences.
  • Using a carrier peptide instead of a whole protein can enhance antibody responses in primed mice.

Purpose of the Study:

  • To investigate if pre-immunization with a protein followed by a B-cell sequence linked to a carrier peptide enhances antibody response to a new B-cell sequence linked to the same carrier.
  • To explore the potential of reusing carrier peptides for developing multi-valent vaccines.

Main Methods:

  • Mice were pre-immunized with a protein.
  • Subsequently, mice received a B-cell sequence linked to a carrier peptide.
  • The antibody response to a new B-cell sequence linked to the same carrier peptide was measured.

Related Experiment Videos

Main Results:

  • Mice pre-immunized with a protein and then a B-cell sequence-carrier peptide conjugate showed an enhanced antibody response.
  • This enhanced response was observed when the new B-cell sequence was also linked to the same carrier peptide.

Conclusions:

  • Carrier peptides can be effectively reused to enhance antibody responses against new B-cell epitopes.
  • This strategy holds promise for developing adaptable vaccines against emerging pathogens by coupling new epitopes to existing carrier peptides.